Houston industrial biotech company Cemvita has announced two strategic moves to advance its operations in Brazil.

The company, which utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals, acquired a complementary technology that expands its IP and execution of scale-up capacity, according to a news release. The acquisition will bring additional synthetic biology toolsets that Cemvita believes will assist with compressing and commercializing timelines.

The company also appointed Luciano Zamberlan as vice president of operations based in Brazil.

Zamberlan will lead operational execution, site readiness and early commissioning activities in Brazil. He brings more than 20 years of experience in biotechnology to the role. He recently served as director of engineering at Raízen, Brazil’s largest ethanol producer and the world’s largest producer of sugarcane ethanol. At Raízen, he coordinated the implementation of four greenfield plants and oversaw operational teams and process optimization for second-generation ethanol (E2G) and biogas.

“I am very pleased to join Cemvita, a company at the forefront of transforming waste into valuable, sustainable resources,” Zamberlan said in the release. “My expertise in scaling-up innovation, coupled with my experience in structuring and commissioning greenfield industrial operations, is perfectly aligned with Cemvita's mission and I'm eager to bring my energy and drive to accelerate Cemvita's industrial performance and contribute for a circular future.”

Cemvita expanded to Brazil in January to help capitalize on the country’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, enacted in 2024. The law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

“These steps enable us to augment Brazil’s longstanding bioindustrial ecosystem with next-generation capabilities, reducing early commercialization risk and expanding optionality for future product platforms,” Marcio Silva, CTO of Cemvita, said in the news release. “Together, they strengthen our ability to move from proof-of-concept to industrial reality.”